NeuroPace Secures $65M to Propel Breakthrough Brain Stimulation Technology for Epilepsy and Beyond

NeuroPace is thrilled to announce the successful closing of a $65,000,000 funding round, a pivotal milestone that underscores growing investor confidence in our groundbreaking work in the field of neurological disorder treatment. With our flagship RNS® System—an award-winning technology developed and manufactured in Silicon Valley, and the world’s first and only medical device capable of monitoring and responding to brain activity—we have already made significant strides in the treatment of epilepsy. This innovative system, akin to a pacemaker that responds to heart rhythms, has transformed the lives of countless patients by providing targeted responsive stimulation tailored to their unique neurological patterns. With this new capital infusion, NeuroPace is poised to accelerate both research and development efforts aimed at expanding the capabilities of our implantable devices. This funding is not only a testament to the innovative potential of our current technology but also a crucial resource that will drive the design, development, manufacturing, and marketing of next-generation solutions for neurological disorders. While our initial focus remains on epilepsy—a debilitating condition affecting approximately 1% of the global population—we are excited to explore the wider potential of responsive neurostimulation in addressing other disabling medical conditions. The support from our investors empowers us to enhance our clinical trials, broaden our reach to more patients, and further our mission of improving quality of life worldwide. We are grateful for this opportunity to continue leading the way in neuromodulation technology and look forward to the promising advancements that lie ahead.